U.S. markets closed

Compugen Ltd. (CGEN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.93-0.41 (-4.92%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.34
Open8.35
Bid7.94 x 900
Ask8.26 x 800
Day's Range7.93 - 8.62
52 Week Range6.74 - 19.90
Volume1,052,922
Avg. Volume1,148,866
Market Cap663.646M
Beta (5Y Monthly)2.32
PE Ratio (TTM)N/A
EPS (TTM)-0.39
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Compugen's COM701 Shows Treatment Durability Beyond One Year in Solid Tumor Patients
    Benzinga

    Compugen's COM701 Shows Treatment Durability Beyond One Year in Solid Tumor Patients

    Compugen Ltd (NASDAQ: CGEN) has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squibb & Co's (NYSE: BMS) Opdivo (nivolumab). Data were presented at the ASCO 2021 Annual Meeting. COM701 and Opdivo combination was well-tolerated with no reported dose-limiting toxicities up to the fifth and final dose cohort. The disease control rate (DCR) was 66.7% with best responses of complete r

  • Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting
    PR Newswire

    Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting

    Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab) in an oral presentation at the ASCO 2021 Annual Meeting, being held virtually on June 4-8, 2021. COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint disc

  • Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities
    PR Newswire

    Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities

    Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that members of its senior management team will participate in a virtual event to discuss data from its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, as a monotherapy and in combination with nivolumab. The data will be presented in an oral presenation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, on June 7, 2021.